In an interview with Dr. William Seeds in Authority Magazine, Jennifer Bright talks about her own journey to IVI, what drives her to improve value assessment, and why collaboration is paramount for success. Read the full interview here.
In a commentary in AJMC, IVI examines how multi-criteria decision analysis has the potential to better understand and assess value for innovative cell and gene therapies which are transforming the lives of patients living with serious diseases. Read the full article here.
Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare [...]
Goal: Identify Areas of Consensus to Ultimately Make the Value Assessment Process Useful to Those Who Receive and Pay for Care Alexandria, VA – July 20, 2020 – The Innovation and Value Initiative (IVI), a non-profit research organization dedicated to improving the science and practice of value assessment, announced today it is awarding a grant [...]
Central to IVI’s work is ensuring patient perspectives are included at the front of all value assessments. This short video explains why and how IVI incorporates lived experience in its modeling.
IVI's Jennifer Bright and Mike Thompson of the National Alliance for Healthcare Purchasers share how employers can use depression as a "test case" for thinking about how to improve the value assessment process, so that we can apply a "purchaser-patient" lens up front. Read the full article on Employers Benefit News here.
The COVID-19 pandemic is raising new questions about how we approach value assessment. As always, IVI urges experts to use transparency, real world data, and seek consensus. Sam Nussbaum, President of the IVI Board of Directors, shares his thoughts in a commentary in STAT. Read the full commentary here.
Authors: Alan Balch and Donna Cryer The vast majority of experts agree that we could, and should, be doing a lot more to include input from patients in value assessment, from conceptualization to data inputs to implementation. The crux of the problem is that in today’s world, we end up with models that assign a [...]
IVI's Jennifer Bright and Amy Miller, former CEO of the Society for Women's Health Research, explain why patient heterogeneity is crucial to consider in any value assessment method. Read the full article here.
Previewing their panel discussion at ISPOR 2020, Lou Garrison and Leah Howard discuss what’s needed to address gaps on value assessment. View the short video clip here.
